Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOTRADECOL vs AVAGE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sotradecol (sodium tetradecyl sulfate) is a sclerosing agent that acts by irritating the intimal endothelium of veins, causing inflammation, thrombosis, and subsequent fibrosis, leading to occlusion of the treated vein.
Avage (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RAR-β, RAR-γ) with high affinity and modulates gene expression, leading to reduced keratinocyte proliferation, differentiation, and inflammation.
Uncomplicated spider veins (telangiectasias) and reticular veins of the lower extremities,Small, uncomplicated varicose veins
FDA-approved for the topical treatment of stable plaque psoriasis (up to 20% body surface area),FDA-approved for the topical treatment of mild to moderate acne vulgaris,Off-label: treatment of photoaging, facial wrinkles, and certain hyperpigmentation disorders
0.5 m L per injection site, multiple sites per session; maximum volume 10 m L per session; intravenous (sclerotherapy) administration; frequency every 4-6 weeks.
Applied topically as a cream 0.05% to affected areas once daily at bedtime.
Terminal elimination half-life approximately 5-6 hours; clinical effect persists longer due to local action at injection site
Terminal elimination half-life is approximately 2-4 hours in patients with normal renal function; prolonged to 12-24 hours in severe renal impairment (Cr Cl <30 m L/min).
Sodium tetradecyl sulfate is primarily metabolized in the liver via sulfation and glucuronidation, with involvement of hepatic enzymes such as sulfotransferases and UDP-glucuronosyltransferases (UGTs).
Tazarotene is rapidly metabolized via ester hydrolysis to its active metabolite, tazarotenic acid. Tazarotenic acid is further metabolized via oxidation and conjugation (glucuronidation). The enzymes involved include esterases and possibly CYP450 isoforms; specific CYP450 enzymes are not well characterized.
Primarily renal; <1% recovered as unchanged drug in urine; majority eliminated as metabolites via bile into feces
Primarily renal excretion (70-80% as unchanged drug) with 10-20% biliary/fecal elimination.
>90% bound to plasma proteins, primarily albumin
Approximately 90% bound to albumin and alpha-1-acid glycoprotein.
0.15-0.3 L/kg; reflects limited distribution primarily to plasma and interstitial space
0.3-0.5 L/kg, indicating distribution primarily into extracellular fluid.
Not applicable; administered via intradermal, intravenous, or endoscopic injection; not intended for oral administration
Oral: 60-70% due to first-pass metabolism; Intravenous: 100%.
No specific dose adjustment provided in labeling; not studied in renal impairment; use caution in severe impairment.
No specific dose adjustment required for renal impairment.
No specific dose adjustment provided in labeling; caution in Child-Pugh class C due to potential for acute hepatic necrosis.
No specific dose adjustment required for hepatic impairment.
Safety and efficacy not established in pediatric patients (age <18 years).
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
No specific dose adjustment required; consider comorbidities and overall health status.
No specific dose adjustment required; however, use with caution due to potential increased sensitivity and skin fragility in elderly patients.
Sotradecol injection is contraindicated for the treatment of patients with underlying arterial disease or with known allergy to the drug. Severe adverse reactions including anaphylaxis, pulmonary embolism, and tissue necrosis have been reported.
Avage is contraindicated in women who are or may become pregnant. Tazarotene is a teratogen, and fetal harm can occur when administered to a pregnant woman. If the drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
Anaphylactic reactions; arterial injection causing tissue necrosis; pulmonary embolism; allergy to the drug; use with caution in patients with thrombophlebitis, hypercoagulable states, or chronic obstructive pulmonary disease; avoid extravasation.
Avoid contact with eyes, mouth, and mucous membranes,Not for use on eczematous or sunburned skin,May cause severe local skin reactions (e.g., redness, peeling, burning, stinging),Photosensitivity: patients should avoid or minimize exposure to sunlight and artificial UV sources,Concomitant use with other photosensitizing agents should be approached with caution
Known allergy to sodium tetradecyl sulfate; acute thrombophlebitis; severe chronic venous insufficiency; arterial disease; uncontrolled diabetes mellitus; sepsis; pregnancy; breastfeeding; incompetent perforating veins.
Pregnancy (FDA Pregnancy Category X),Women of childbearing potential unless using effective contraception and have a negative pregnancy test within 2 weeks prior to therapy,Hypersensitivity to tazarotene or any component of the formulation
No specific food interactions are known. Patients should maintain adequate hydration and avoid excessive alcohol intake, which may increase the risk of bleeding or thrombosis. No dietary restrictions are required.
AVAGE should be taken with a meal containing fat (e.g., whole milk, peanut butter) to enhance absorption. Avoid excessive vitamin A supplements as they may add to toxic effects. Grapefruit juice may increase isotretinoin levels; consider avoidance.
FDA Pregnancy Category C. No adequate human studies; animal studies show fetal harm. Use only if benefit outweighs risk. First trimester: potential teratogenicity. Second/third trimester: risk of fetal bradycardia, arrhythmias, or death due to systemic absorption if injected near cervix.
FDA Pregnancy Category X. First trimester: High risk of major congenital malformations including craniofacial defects (cleft lip/palate), cardiovascular abnormalities, and neural tube defects. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and premature closure of the ductus arteriosus. Avoid use throughout pregnancy.
Unknown excretion in human milk. Due to low systemic absorption after local injection, risk to breastfed infant is likely low. Caution recommended; M/P ratio not established.
Contraindicated in breastfeeding. Excreted into human milk; M/P ratio not established. Risk of serious adverse effects in nursing infant, including keratoderma-like skin changes and potential for growth impairment.
No dose adjustment required; however, use only when clearly needed. Systemic absorption is minimal after local injection, and pharmacokinetic changes in pregnancy are unlikely to alter efficacy or safety.
No dose adjustment applicable; drug is absolutely contraindicated in pregnancy due to teratogenicity. No data on pharmacokinetic changes; theoretical increased clearance due to expanded plasma volume may occur but is clinically irrelevant given contraindication.
Sotradecol (sodium tetradecyl sulfate) is a sclerosing agent used for the treatment of varicose veins. Administer via direct injection into the vein using a fine needle; avoid extravasation as it causes tissue necrosis. Perform a test dose (0.5 m L) to assess for hypersensitivity. Compression stockings should be worn for 1-3 weeks post-injection. Do not exceed 10 m L per session; maximum total dose per session is 10 m L of 1% or 2 m L of 3% solution. Use caution in patients with arterial disease, recent thrombosis, or known hypersensitivity. Delayed skin pigmentation may occur. Allergic reactions, including anaphylaxis, have been reported.
AVAGE (isotretinoin) is highly teratogenic; confirm negative pregnancy test within 5 days before starting therapy and monthly thereafter. Monitor triglycerides, liver function, and CBC at baseline and monthly. Avoid blood donation during treatment and for 1 month after discontinuation. Use with caution in patients with depression; monitor for mood changes. Administer with food to increase absorption.
This medication is injected directly into your varicose veins to cause them to collapse and fade.,You may experience a burning sensation at the injection site, which is normal.,Wear compression stockings as directed, typically for 1-3 weeks after treatment.,Avoid strenuous exercise and prolonged standing for 24-48 hours after injection.,Contact your doctor if you develop severe pain, swelling, redness, or skin ulcers at the injection site.,Notify your doctor if you have a history of blood clots, allergies, or are pregnant or breastfeeding.
AVAGE can cause severe birth defects; females must use two effective forms of contraception and have monthly pregnancy tests.,Do not donate blood while taking AVAGE and for 1 month after stopping.,Avoid exposure to sunlight or tanning beds; use sunscreen and protective clothing.,Report any signs of depression, mood changes, or thoughts of self-harm immediately.,Take each dose with a full meal to ensure proper absorption.,May cause dry skin, lips, eyes; use moisturizers and artificial tears as needed.,Avoid waxing or laser treatments during therapy and for 6 months after.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOTRADECOL vs AVAGE, answered by our medical review team.
SOTRADECOL is a Sclerosing agent that works by Sotradecol (sodium tetradecyl sulfate) is a sclerosing agent that acts by irritating the intimal endothelium of veins, causing inflammation, thrombosis, and subsequent fibrosis, leading to occlusion of the treated vein.. AVAGE is a Topical Retinoid that works by Avage (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RAR-β, RAR-γ) with high affinity and modulates gene expression, leading to reduced keratinocyte proliferation, differentiation, and inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOTRADECOL and AVAGE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOTRADECOL is: 0.5 m L per injection site, multiple sites per session; maximum volume 10 m L per session; intravenous (sclerotherapy) administration; frequency every 4-6 weeks.. The standard adult dose of AVAGE is: Applied topically as a cream 0.05% to affected areas once daily at bedtime.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOTRADECOL and AVAGE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOTRADECOL is classified as Category C. FDA Pregnancy Category C. No adequate human studies; animal studies show fetal harm. Use only if benefit outweighs risk. First trimester: potential teratogenicity. Second/third tri. AVAGE is classified as Category C. FDA Pregnancy Category X. First trimester: High risk of major congenital malformations including craniofacial defects (cleft lip/palate), cardiovascular abnormalities, and neural t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.